Last Updated on January 9, 2024 by The Health Master
BENGALURU -India’s drug regulator Drugs Controller General India (DCGI) on Tuesday allowed vaccine maker Serum Institute to enroll kids aged 7-11 years for its C-19 vaccine trial as the country prepares to protect children from the C-19 virus.
It has already administered more than 870 million doses to adults among its population of nearly 1.4 billion.
“After detailed deliberation, the committee recommended for allowing enrolment of subjects of 7 to 11 years of age group as per the protocol,” a subject expert panel of the Central Drugs Standard Control Organization (CDSCO) said.
Serum Institute is already conducting a trial of its C-19 vaccine, a domestically produced version of U.S. drugmaker Novavax’s shot, in the 12-17 age group and has presented safety data for an initial 100 participants.
So far, only drugmaker Zydus Cadila‘s DNA C-19 vaccine has received emergency use approval in India to be used in adults and children aged 12 years and above.
NPPA fixes retail price of 23 formulations: September 2021
DCGI’s nod to AstraZeneca to import, market Selumetinib Capsules
New 3D Printed Vaccine Patch offers greater protection than jabs
PCI publishes Syllabus for Diploma in Pharmacy Course 2021-22
Medical Devices registration will benefit industry: DCGI
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
